Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.
Alice Lin-Tsing YuAndrew L GilmanM Fevzi OzkaynakArlene NaranjoMitchell B DiccianniJacek GanJacquelyn A HankAyse BatovaWendy B LondonSheena C TenneyMalcolm A SmithBarry L ShulkinMarguerite ParisiKatherine K MatthaySusan L CohnJohn M MarisRochelle BagatellJulie R ParkPaul M SondelPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Immunotherapy with dinutuximab improved outcome for patients with high-risk neuroblastoma. Early stoppage for efficacy resulted in a smaller sample size than originally planned, yet clinically significant long-term differences in survival were observed.